Home
Clinical Resources Search
PQI: Selinexor (Xpovio®) Patient Management

Selinexor (Xpovio®) Patient Management

Last Updated: November 14, 2023

By: Jeremiah Moore, PharmD

About this PQI

This PQI will provide background on the novel medication selinexor for patients with multiple myeloma (MM) who have received at least one prior therapy, relapsed, refractory multiple myeloma (RR-MM), and relapsed, refractory diffuse large b-cell lymphoma (RR-DLBCL) and discuss effective practices to maximize the use of selinexor therapy.

More About This PQI

PQI in Action Articles:

Selinexor_xpovio_patient_management pdf 1.21MB

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care.

Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI

Find Similar Resources

All Resources

PQI PQI in Action PQI Podcast Toolkit Treatment Support Kit Video Diffuse Large B-Cell Lymphoma (DLBCL) Hematological Malignancies Lymphoma Multiple Meloma (MM) Multiple Myeloma Selinexor Xpovio

PQI

PQI in Action: Nirogacestat (Ogsiveo) use in Management of Adults with Progressing Desmoid Tumors (or fibromatosis or aggressive fibromatosis)

Last Updated: 10/04/2025

PQI in Action

PQI in Action: Abiraterone acetate (Yonsa) Patient Selection and Management

Last Updated: 09/10/2025

PQI in Action

PQI in Action: Enfortumab Vedotin-ejfv (Padcev®) and Pembrolizumab (Keytruda®) Management for Advanced or Metastatic Urothelial Carcinoma

Last Updated: 09/10/2025

PQI Podcast

Frequently Searched

Supported by

Selinexor (Xpovio®) Patient Management

About this PQI

More About This PQI

PQI in Action Articles:

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Sutimlimab-jome (Enjaymo) for the Management of Hemolysis in Cold Agglutinin Disease (CAD)

PQI: Datopotamab deruxtecan (DATROWAY): Prophylaxis and Management of Adverse Events

PQI: Eflapegrastim-xnst (Rolvedon) for Chemotherapy-Induced Neutropenia

PQI: Revumenib (Revuforj) for the Management of Acute Leukemia

PQI in Action: Epcoritamab (Epkinly) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

PQI in Action: Nirogacestat (Ogsiveo) use in Management of Adults with Progressing Desmoid Tumors (or fibromatosis or aggressive fibromatosis)

PQI in Action: Abiraterone acetate (Yonsa) Patient Selection and Management

PQI in Action: Enfortumab Vedotin-ejfv (Padcev®) and Pembrolizumab (Keytruda®) Management for Advanced or Metastatic Urothelial Carcinoma

S9 E10: Advancing Clinical Research

S9 E9: The Realities of Ethics in Oncology

S9 E8: Mental Strength at Work

S9 E7: A Haven of Healing

Toolkit: Simplify CLL Tracking in Oncology Practices

Toolkit: Optimize CLL Care in Epic

Treatment Support Kit: Elranatamab

Treatment Support Kit: Mirdametinib

Treatment Support Kit: Abemaciclib

Treatment Support Kit: Temozolomide

Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide

Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Rituximab and Hyaluronidase

PQI in Action: Epcoritamab (Epkinly) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Etoposide

S7 Ep 8: Sickle Cell Disease Insights

Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Lenalidomide and Tafasitamab

RICE

ICE

Pomalidomide

Selinexor

PQI: Ixazomib (Ninlaro®) In the Treatment of Multiple Myeloma

Melphalan

Daratumumab and KRd

Daratumumab and VRd

Daratumumab and Rd

Daratumumab and Pd

Selinexor

PQI in Action: Selinexor (Xpovio®)Patient Management

Selinexor

PQI in Action: Selinexor (Xpovio®)Patient Management

S9 E10: Advancing Clinical Research

Amivantamab and Lazertinib

Lenvatinib and Pembrolizumab

Axitinib and Pembrolizumab